THEIR

HURTS

Discover unspoken trade-offs in managing hemophilia A^1,2

Are your patients compromising bleed protection or accepting administration-related challenges?

Explore Voices of Hemophilia Roundtable Discussions, a video that discusses unmet needs and the potential benefits of increasing shared decision-making.

Learn more

Nikola lives with hemophilia A.

^aBased on a real-world study with 354 people with hemophilia A. Analysis is limited to ABRs in medical records and PROs from the survey and may have been limited by medical record discrepancies, recall bias, and potential reporting bias for bleeds.³

ABR=annual bleed rate; PROs=patient-reported outcomes.

RESTORING THROMBIN GENERATION TOWARD THE NORMAL HEMOSTATIC RANGE IS KEY TO ACHIEVING AND MAINTAINING EFFECTIVE HEMOSTASIS⁴

Despite treatment advances, bleeds persist that can hold some patients back¹

Uncover their truth

Insufficient thrombin generation and weakened clot structure can contribute to an increased risk of bleeding⁵

Explore more

Consider the treatment challenges that can hinder the goal of zero bleeds⁶

Discover real experiences

HOW ARE TREATMENT
APPROACHES EVOLVING?

Across treatment classes, the goal is to achieve effective hemostasis by increasing thrombin generation capabilities⁶
Measuring thrombin generation in clinical trials may be an approach to evaluating hemostatic function of nonfactor therapies⁶
Different parts of the coagulation cascade are being targeted with the goal of achieving hemostasis by increasing thrombin generation capabilities^7,8
Researchers are exploring how to design molecules to evolve pharmacokinetics, such as half-life and clearance rates, which may impact dosing frequency⁷

Explore treatment approaches

David lives with hemophilia A.

IT IS IMPORTANT TO TAKE A DEEPER LOOK

People living with hemophilia A may be making trade-offs by compromising bleed protection or accepting administration-related challenges, which can negatively impact their lifestyle.^1,2

ARE YOUR PATIENTS STRUGGLING WITH BREAKTHROUGH BLEEDS?

See results from real-world studies

Go now

STAY UP TO DATE
WITH THE LATEST INFORMATION

Get updates and communications on hemophilia A from Novo Nordisk as they become available.

References

Wheeler AP, Amos LE, Gupta S, et al. Treatment of haemophilia A without inhibitors: real-world treatment patterns and clinical outcomes in the US. Haemophilia. 2026;0:1-12.
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition [published correction appears in Haemophilia. 2021;27(4):699]. Haemophilia. 2020;26(suppl 6):1-158.
Data on file. Novo Nordisk Inc; Plainsboro, NJ.
Maneikis K, Krumb E, Hermans C. Normalization in hemophilia: conceptual foundations and clinical implications. Res Pract Thromb Haemost. 2025;9(7):103200.
Ząbczyk M, Natorska J, Undas A. Novel factors affecting fibrin clot formation and their clinical implications. Polish Archives of Internal Medicine. Published online November 6, 2024.
Sidonio RF Jr, Hoffman M, Kenet G, Dargaud Y. Thrombin generation and implications for hemophilia therapies: a narrative review. Res Pract Thromb Haemost. 2022;7(1):100018.
Teranishi-Ikawa Y, Soeda T, Koga H, et al. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state. J Thromb Haemost. 2024;22(2):430-440.
Lillicrap D, Lenting P. Hemophilia A treatment innovation: factor VIII mimetic bispecific antibodies-generational enhancement. J Thromb Haemost. 2024;22(2):352-355.

THEIR

HURTS

Discover unspoken trade-offs in managing hemophilia A1,2

RESTORING THROMBIN GENERATION TOWARD THE NORMAL HEMOSTATIC RANGE IS KEY TO ACHIEVING AND MAINTAINING EFFECTIVE HEMOSTASIS4

HOW ARE TREATMENT APPROACHES EVOLVING?